TY  - GEN
AU  - Rayson,D
AU  - Suter,T M
AU  - Jackisch,C
AU  - van der Vegt,S
AU  - Bermejo,B
AU  - van den Bosch,J
AU  - Vivanco,G L
AU  - van Gent,A M
AU  - Wildiers,H
AU  - Torres,A
AU  - Provencher,L
AU  - Temizkan,M
AU  - Chirgwin,J
AU  - Canon,J L
AU  - Ferrandina,G
AU  - Srinivasan,S
AU  - Zhang,L
AU  - Richel,D J
TI  - Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
SN  - 1569-8041
PY  - 2012///1022
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Doxorubicin
KW  - Female
KW  - Heart Diseases
KW  - chemically induced
KW  - Humans
KW  - Middle Aged
KW  - Polyethylene Glycols
KW  - Stroke Volume
KW  - drug effects
KW  - Trastuzumab
KW  - Ventricular Function, Left
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdr519
ER  -